<SEC-DOCUMENT>0001193125-15-033910.txt : 20150205
<SEC-HEADER>0001193125-15-033910.hdr.sgml : 20150205
<ACCEPTANCE-DATETIME>20150204180204
ACCESSION NUMBER:		0001193125-15-033910
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20150205
DATE AS OF CHANGE:		20150204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		15576722

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d865285d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No. 28</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(4)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g865285g11s64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;), by that certain Prospectus Supplement No.&nbsp;12 dated December&nbsp;5, 2013 (&#147;Supplement No.&nbsp;12&#148;), by that certain Prospectus Supplement No.&nbsp;13 dated January&nbsp;8, 2014 (&#147;Supplement
No.&nbsp;13&#148;), by that certain Prospectus Supplement No.&nbsp;14 dated February&nbsp;10, 2014 (&#147;Supplement No.&nbsp;14&#148;), by that certain Prospectus Supplement No.&nbsp;15 dated February&nbsp;12, 2014 (&#147;Supplement
No.&nbsp;15&#148;), by that certain Prospectus Supplement No.&nbsp;16 dated February&nbsp;18, 2014 (&#147;Supplement No.&nbsp;16&#148;), by that certain Prospectus Supplement No.&nbsp;17 dated March&nbsp;3, 2014 (&#147;Supplement No.&nbsp;17&#148;),
by that certain Prospectus Supplement No.&nbsp;18 dated March&nbsp;20, 2014 (&#147;Supplement No.&nbsp;18&#148;), by that certain Prospectus Supplement No.&nbsp;19 dated May&nbsp;13, 2014 (&#147;Supplement No.&nbsp;19&#148;), by that certain
Prospectus Supplement No.&nbsp;20 dated June&nbsp;9, 2014 (&#147;Supplement No.&nbsp;20&#148;), by that certain Prospectus Supplement No.&nbsp;21 dated August&nbsp;13, 2014 (&#147;Supplement No.&nbsp;21&#148;), by that certain Prospectus Supplement
No.&nbsp;22 dated August&nbsp;18, 2014 (&#147;Supplement No.&nbsp;22&#148;), by that certain Prospectus Supplement No.&nbsp;23 dated November&nbsp;12, 2014 (&#147;Supplement No.&nbsp;23&#148;), by that certain Prospectus Supplement No.&nbsp;24 dated
December&nbsp;1, 2014 (&#147;Supplement No.&nbsp;24&#148;), by that certain Prospectus Supplement No.&nbsp;25 dated December&nbsp;10, 2014 (&#147;Supplement No.&nbsp;25&#148;), by that certain Prospectus Supplement No.&nbsp;26 dated
December&nbsp;11, 2014 (&#147;Supplement No.&nbsp;26&#148;), and by that certain Prospectus Supplement No.&nbsp;27 dated December&nbsp;30, 2014 (&#147;Supplement No.&nbsp;27&#148;, and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2,
Supplement No.&nbsp;3, Supplement No.&nbsp;4, Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement No.&nbsp;9, Supplement No.&nbsp;10, Supplement No.&nbsp;11, Supplement No.&nbsp;12, Supplement
No.&nbsp;13, Supplement No.&nbsp;14, Supplement No.&nbsp;15, Supplement No.&nbsp;16, Supplement No.&nbsp;17, Supplement No.&nbsp;18, Supplement No.&nbsp;19, Supplement No.&nbsp;20, Supplement No.&nbsp;21, Supplement No.&nbsp;22, Supplement
No.&nbsp;23, Supplement No.&nbsp;24, Supplement No.&nbsp;25, and Supplement No.&nbsp;26, the &#147;Supplements&#148;), which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is
being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on
February&nbsp;4, 2015 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible
Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements.
This prospectus supplement updates and supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the
information in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol
&#147;ABIO.&#148; On February&nbsp;4, 2015, the last reported sale price of our common stock was, rounded to the nearest penny, $0.72 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 22 of our quarterly report on Form 10-Q for the period ended September&nbsp;30, 2014 before you decide whether to invest in shares of our common stock.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities
or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is February&nbsp;4, 2015 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;4, 2015 (February 4, 2015) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;4, 2015,
ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that the U.S. Patent and Trademark Office issued a patent on methods and compositions of the S-isomer formulation of Gencaro (bucindolol hydrochloride). The press release is furnished as Exhibit 99.1
hereto, the contents of which are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Press Release titled &#147;ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-Isomer Formulation of Gencaro&#148; dated February 4, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&nbsp;4, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Christopher Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-Isomer Formulation of Gencaro&#148; dated February 4, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g865283g60q71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES PATENT ISSUANCE FOR METHODS AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPOSITIONS OF S-ISOMER FORMULATION OF GENCARO </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:63%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patent
Includes Methods for Treating Multiple Cardiovascular Disease Indications </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, February&nbsp;4, 2015</I> &#150; ARCA biopharma, Inc.
(Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods and compositions of the S-isomer
formulation of Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride). The patent (USP# 8946284), entitled &#147;Methods and Compositions involving (S)-Bucindolol,&#148; provides intellectual property protection in
the United States for the use of S-isomer Gencaro (Gencaro substantially free of its R-stereoisomer) as a potential treatment for right ventricular heart failure, congestive heart failure, hypertension, angina, myocardial infarction, cardiac
arrhythmia, mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with the
USPTO&#146;s issuance of this patent, which we believe broadens our intellectual property protection around Gencaro in multiple important cardiovascular disease indications which impact large patient populations globally,&#148; said Michael
R.&nbsp;Bristow, President and Chief Executive Officer of ARCA. &#147;This patent is a result of ARCA&#146;s continued focus on innovation in cardiovascular drug development. The S-isomer of Gencaro contains the high affinity beta-1 and beta-2
receptor-blocking action as well as nitric oxide generating activity. In GENETIC-AF, our on-going Phase 2B/3 clinical trial, we are evaluating racemic (contains both S and R isomers) Gencaro as a potential treatment for the prevention of atrial
fibrillation in a pharmacogenetically defined heart failure population at high risk of developing recurrent atrial fibrillation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being evaluated as a potential treatment for atrial fibrillation in the Phase 2B/3
GENETIC-AF clinical trial, which is enrolling patients in the United States and Canada. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first approved
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, the potential for S-isomer Gencaro to possibly be a treatment for several different cardiovascular indications, the potential for genetic variations to predict individual
patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many
factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of
competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g865283g60q71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g865283g60q71.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``(!`0(!`0("
M`@("`@("`P4#`P,#`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,
M!PD.#PT,#@L,#`S_VP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!5`-L#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]_***9<7"6L+R2NL<<8+,S'"J!R23V%)NVK`?17@7Q'_X*$^$_"&I
MR6>D6=[XCEA8H\L#+#;Y'7:[9+?4#'O7-Q_\%++>4`CP5?$'O_:*?_$5\5BO
M$;AO#U'2J8I7792DOOC%K\3V*?#^83BIQI.S[M+\&[GU#17S))_P4?BBB1SX
M*OML@)'_`!,4['']RH'_`."F-M$!N\%WP!_ZB*?_`!%8?\1/X8_Z"O\`R2?_
M`,B:?ZN9C_S[_&/^9]145Y5\%/VP/"?QJU!-.MWN-*UB096SO`%,I[B-P<,?
M;@^U>JU];EF:X/,*"Q."J*<'U3_!]GY/4\K$86K0G[.M%Q?F%%%%>@8!15>_
MU>TTM[=;JYM[9KN400"60(9I""0BY^\Q`/`YX-6*`"BBC(SC(S0`444FX9QD
M9]*`%HHHH`***9/.EM$TDCI&BC)9C@`?6@!]%<Q_PNOP8=0-I_PEWAC[4#@P
M_P!J0>8#Z;=V:Z*UO8;V,/#+%,C#(9&#`CUR*`):***`"BH-2U.VT:PFN[RX
M@M+6W4O+--((XXU'4LQX`]S4RL'4,I!!&01T-`"T444`%?/_`/P4-^(EWX3^
M%EAH]H\D)\17+13NIP3#&H9D_P"!$KGV!'>OH"OF'_@I3'YFF>#!@$?:;GK_
M`+L=?$>(^)J4.&\54I.SLE\I2BG]Z;1['#].,\PI*2NK_DFSY>\*^%GUZ[2)
M=JN_"!CM5CZ9[9]Z].\$?!R77+:_LC;O'?V:&YCB9<,VS_6)CUV_-_P`^M5O
MA7H&D:M(D=[+<:>S'`F1!-$/JO#`?0GZ5[KKOC.T^$]AH1#:=K?B*<-]@O(7
M8*;<#;NF&`6P25`Z\=>*_G/AKA[#5:3Q6,DE!;N]]'I;EWYM?=TLWI='WF8Y
MA4C)4Z2U>WY[[6[]3S2\^!MQJ'AWPTEO`7N=2,Z(`.O[P`$_K^`KB_&OPO\`
M,UB[@L4\VUL05\X@J@1>#(Q[`G)_$`5]8>`;C6M9TN.\<Z>R6Z-Y4:VZQB$-
M][81RN?QKE_BGX-TVY\)P+%?6>BZ,"6>+:TUW>3#ABP&-V#P,G'.>,U];F/!
MN%JX/ZQ0NM$];1;48J-TV[).5VVW_*DKGDX?.*D:WLY]WMKNV_7;;YGQG=PS
M>'=5CGM9989;:020S*=KHP.0P]#D5^C_`,$O&DOQ$^$OA[6I\&XU"RCDF(&`
M9,8<X_W@:^"_B1IUE!-(MI%,4'22=AN/_`1P/UK[7_9'&/V;_"?_`%YG_P!&
M-71X,RJ4<VQ.$YKQ<+VZ74DD_N;'Q;RSPM.K;6]OO7_`/1J**X_]H#XS:7^S
MQ\$_%'C?67":=X9TZ6^D!)'F%5^2,8SR[E5'NPK^CFSX!(_+3_@NG^VWK%E^
MU=X,\.^%+J>.#X27D&L3SQ@^4=7;$L:$_=+1P@<?]-G%?JI\%?BKIOQR^$?A
MOQAI$BRZ;XDTZ'4("#G:)$#%3[J25/N#7YR_$?\`85U/XH?\$=/$7BO6K9I?
MB5XEU&7XK7C$9D\R0%S!G&2!9,0%[-76_P#!NY^TR?'_`.S]KWPVO[@O?^![
MK[78!F)9K&Y);`SQA)@XP.@=:YX2:GKU-Y).&G0_12O'_P!IS]A;X=_M;W5K
M>>+K'5AJMA`;:UU#3-7N;"YMX]Q;`,3A3\Q)^937L%%;M)[F*;6Q_/W\/OAW
MXD\5?\%&+?X(WGQ%\?\`_".+XQN-"EF77;D3/;0R2`D?/M#LD>,XP"<XK]4;
MS_@BU\$I-)\JVC\>:??J"4U*W\7:@+Q&[,&:0J2#SRN*_.'X.#/_``7L'_92
M=1_]"N*_="2188V=V"JHR23@`>M<U"*:=SHK2:M8_'72/V[/BW_P2P_;EOOA
MEXY\8:M\1?A]9WT,;'5Y!<7B6$X5HKF*4_.LB(X+(6*DHPP."/V(@G2Z@22-
M@\<BAE8'(8'D&OP^_;'^'E]_P4^_X*Q^(M)^&4,FKZ7#)::7?ZO%\]G9PVZ+
M'/<M(/EV!MX7G+D#;G-?M'XEUNS^#WPIU#4I5EEL/"VDR7+*#EWBMX2Q'U*I
M5T6[M="*J6CZGRM_P5(_X*P:9^PW81^%O#-M:^(?B7JL(DBM)"6M](B;A)K@
M+RS-_!$""W4D#&>'_9G_`.";?C?]J_1['Q[^U1XP\4^);S4@+RR\$I>R6&G:
M8C<@3Q0E1O*GF-<;0<,6.<?$_P#P3(\.W/[>_P#P5.M_%7C0C5&2>Z\77\<Q
M!5VB*_9XMIR"B2/"-O3;'BOW:HA^\O)[#G[B45N?/=Y_P2A_9QO]`739/@]X
M+%L@P&2T,<P_[:J1)GWW5\'_`+>O_!,J[_X)\^*_#WQC^%>K^()/`WA[6;*Y
MU?1IK^623246="'5L_O+<G"E7R5+#E@3C]=*SO%_A#2_'_AB_P!%UO3[35=(
MU.%K>[L[J(2PW$;#!5E/!!JY4XM$1J23U+MG=)?6D4\9S',@=3TR",BI*CM+
M2.PM(H(46.&%!'&BC`50,`#Z"EGG2U@>61UCCC4L[,<!0.22?2M#,_/O_@X.
M_:4D\#?LX6/PTTHR2:GXX?[7J8B!)M],MW0LS8'"O,8DS[,*]O\`^"1_[3)_
M:?\`V'_"FH7=S]HUWPZAT#5BS$N9K<!4=B>27B,3D^K&O&?V>/A#9?\`!3#7
MOVA?B;KB)+H'C.WF^'_@YY5#K;6%KR;I!UR]SMD!!'*$5\W_`/!!#XTWWP`_
M:\\8?!_Q'YED_B-985@E.T0ZG8LX9<$\%H_,''),:US<S4U)[,Z.5.#2W1^Q
MU%%%=)SA7S)_P4AN#;6'@UAM_P"/BZ^\H(^['ZU]-U\Q_P#!2VRG/ACPG=HC
M&&WO)XW<#A&9%*C\=C?E7P?B:F^&<5R]H_\`I<3V^';?VC2OY_DSA?@?K^IN
MRR00:'#!'C=<WEG`B(/7<RY)]ADUT?[36GWE^=%\6Z=)%JUCID'V#49;*U:.
M*W?>9%<#^Z=Y!/0$#.,UX7X'\1(+J,W4[I#&1N;[S`>BCU/Y5[[\-OCOLD-Q
M(!;:-HENWV:R4Y661_E0.?XV))8D]E.`*_!\@S+#XO`RR[%5'%2M9WNXM._-
M:Z7*K:WNWM&UVU]ECL-4I5UB*<4[=.]]+7[OIVZ^>9X,_:/^RZ6EM#*6>0;5
M1/F9CZ`#K7I<VHW?AWP'':7-UI5CK=RS74EIJ=N&&V3&U0[`J#@#(/<XR,5C
M6/QATCP[9^'=1_LS2HWNC.M^\%G''*P#[=P*@$$`Y&*\^^)/Q4-PESHNIS"[
MCL9'6TO%.Z2$=N?XXV&#@\CJ/0_1PS&GE^'E*IB/:2<4EHXJ*DHRW4FTVM$]
MDTTTT[KSGAG7J+EI\JO=];V;7;9?>[Z=CB?C)K=_%>2Q7=I86SY)_=6<*J?H
MRC!'T-?7G[)!W?LX^%#ZVA_]&/7P1XFUR261XA(=F>0&RI]Z^_?V5M.ETK]G
MCPE#,NV3[`LF/9B6'Z$5IX0XB6(SW$UM6O9O?7[4>I7%%-4\#3C_`'OT9Z!7
MP1_P5X\1^(/VCOBG\.OV;_`T.GZCK'B*?_A)=>@O)VBM18VI+1Q3NF75'96)
MP,_*N.HK[D\:>,]+^'?A+4==UN^MM,TC2;=[J[NIW"1P1H,LQ)]J^&?^"1=T
MW[5WQ\^,_P"T=J:[IO$.J_\`"-Z#%)M+V&GP*CA<<E6*F`'U*L>]?T34=[1[
MGPL-/>['JRZA^UHND#3QX*_9]%B(?L_D#6=2""/;MV8\GICBOS%_9#UC7_\`
M@F7_`,%6K'0?%<=CI,,]_P#V'JZ02N]FMI>[6BDC=]I:-&:%@S#.$;/.:_=V
MOR8_X.0OV?H-)\3^!/B?9*D,^J*_A_4"@PSO&#-;R9]0OFK_`,!6LZT;+F70
MNE*[Y7U/UGZT5\]?\$Q?VN++]K[]DGPUK+7\-QXFTFV33-?@W@S0W<0VF1EZ
M@2@"0'&#N([&OH6MXM-71BTT[,_!'2/`D7Q._P""UVI^'YM2UG1XM5^(>HPM
M>Z3=FTO;;]Y,=T4HY1N.H[$U[Y_P64_8[^*/[/GPWM?$^@_%CXJ>,?AR66RU
M>PUK79;F73'?Y4D8IM$D+D[3N7Y6*CD-QXE\'_$NGQ?\%TH]1>\MTL9/B7?*
ML[2`1L6EG1?FZ<L0!]17[D?$#P'I'Q1\$:MX<UZRAU+1M;M9+*]MI1E)HG4J
MRG\#UZ@\UR4J:DI(Z:D^5IGRA_P13_:*\"?&O]E.VTOPUX?T#PEXD\+".S\0
M:;IMLENL\NW"7F`,LLH!.220P=<\"OHS]J#PM<>./V;/B!H]HDLEWJGAS4+6
M!(QEWD>VD55'N20/QK\3M9@\9_\`!$__`(*(,]G]IO-%@D+PA\[/$.B2O]QC
MP#*H&,_PRQYZ'!_</X-?&/PY\?OAMI7BSPIJ=OJVB:Q`L\$T3`E<C)1P#\KJ
M>&4\@@@UK2E=<KW1G4C9\RV/QA_X-\/$5MH'[?365VWDW&K>&KVTMT9>6E1X
M92OL0D3G_@-?N-7XL?\`!1O]C[QA_P`$T_VN[+XW_#JS=O!LNL#5[66)&:+1
M[EV)EL[@#[L$FYPI/!5RN<CG]3/V./VSO!G[;'PEL_$_A2_B^T;%74M+DD'V
MO2I\?-'(G7&?NO\`=88([@*A[MX,=;7WUL>MT45X+^W_`/M[^%/V%/@[>ZOJ
M=W:W?B>\A=-#T42`SW\^"%9E!RL*GEWX``P#D@5NVDKLQ2;=D>]5\N_\%<OC
M_??!W]D^Z\/^'7F;QK\3KN/PGH,4#$3&2X.V61<<_+&6&1T9TKT#_@G_`*AX
MEUO]C7X?:KXQU:YUOQ)KFE+JU]=SDEW:Y9IU7GHJI(J@#@!0!Q7RAX1^(FG?
M\%"/^"ST36=]%?\`@G]G_2YIK#RW#0WNHEUB>9><$+*P`8<'[.I[U$Y:)+J7
M&.M^QZ'^SO\`#+]J3]F?X)^&_`GA[PC\"/[(\-6:VD+S:YJ1EF/+/(^(<;F<
MLQQQDU^=O_!0[P;\4?V.?V[]#^*_B31_"^A:]K]]'XDM%\.7,L^GR3P,BSIN
ME56#O@,X(Q^^SW-?O!7Q%_P7M_9ZB^+O[$MQXGA1?[4^'=Y'JD;9`W6\A$,Z
M>_#*^/6,5%6G[NG0NG4][7J?7OPG^).F_&/X9:!XKT>59M+\16$.H6S!@WR2
M(&`)'<9P?<&N@K\[?^#?#]K6U\??`&_^%FJZC$->\%W#S:7!+*/,N=/E)?"`
M\D12%P<=`Z5^B5:0ES13,IQY78*YOXL_"[3?C%X%O-!U16$%T`R2I]^WD'W9
M%]P?S&1WKI**SQ.&I8BE*A7BI0DFFGLT]T.G4E3DIP=FMCX"\?\`[%_C_P"'
M^K2)::5)KUF#F.YT_#[Q_M1D[E/M@CWK.LOA'\1;6U$/_"'>)`F[>V+-N3T'
MY<_F:_0ZBOR'$>"N5RJN="O4@GTT=O*[5_ON_,^JAQ?B>5*I"+??4^`;SX<?
M$2XTZT@_X0[Q(1;!P/\`0W_B;-96I_!GXCZNR!O!_B0L%$>3:-R!P/R&!]!7
MZ)T5G/P5P4_CQ51[?R]/D./%U6.U*/XGQ9\#/V#/$/B;7;>]\80#1](A</):
MF0-<W8'.W"Y"*>Y)S[5]GVEK'8VL<,*+'%"H1$485%`P`!Z`5)17Z#POPAE^
M0T)4L$FW+XI2UD[;=E9=$D>'F6:U\=-2K;+9+9'@/[27_!.GP=^UGXDNKOQO
MXC^(NH:3<F-O^$?@\12VVCQM&H`98(P.<_,22>237,_"?_@DA\./@%KR7W@+
MQ'\4/!JFXBN+BTTSQ3.MK?-&00)HW#!P1E3GL2*][^-7CB7X;?"S6]=AFM(9
MM-M6EC-RK-&S]%4@$$EB0!SU(JK\`-2\0:[\*M+U/Q/,DFKZLGVUTCC$:6Z/
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MN,_A7O\`^SE^RG8_LTM>IIWC+XB^([.ZACACM/$FO/J<-DJ9P8=Z[D)!P>3D
M`5WO@OQSI/Q$T)-3T6]CU"PD=HUGC!"LRG#8R!G![T[QOK;>&_!^IZBL]M;&
MQMI)_-N%+11A5))8`@D<=C248K5(;E)Z,\K_`&R/V!_AW^W5H>C67CNSOV?0
M;AI[.[T^Y^S7,89</$7P<QMA21CJH((KSKX=_P#!'GX8?!>Y,W@7Q#\4_!$T
MC*TYT;Q;<0K=%3D&1&W(W_?->S?LM>*_$7Q!^%%MXA\2S1M>:W*]Q!#%&(XK
M>#[J*HY/(!;+$GYJ]'H48R]ZP.4E[MRIJFA6>O:+-IVH6UOJ-C=1&&>"ZC66
M.X0C!5U8$,".H(P:^3_%W_!&/X7P>.O^$J^'&J^,O@YXEW9-WX3U-H(V4G++
MY,@=`I/\(POM7UW13<4]R5)K8^7Q^PK\5KA9(+G]J?XHM:,"H$&DZ5#.`1CF
M40$Y]P`:Y>#_`((;_!?7M8?5_&UUX\^(OB"Y(:[U+7O$,TDUS@8P?+V#;[=J
M^R**7LX]2O:2/(?CO^QGH7Q\\.:1H=WXE\>^&_#VD61T\:5X<UQ]-M;R':JA
M)@@W.%5=H^8<$^M>0>$O^")?P9^&FM1ZIX.O/B+X+U>)&C6_T7Q3<V]QL/52
MQW`J<#C&.*^O:*;A%[H2G):)F=X0\._\(CX5T[2_M^HZI_9UNEO]LU";SKJY
MVJ!YDKX&YSC).!DDUX9^T7_P3?\`"7[5.OZC<>,O%WQ/O=)U*2.5]`@\220:
M1$44!0D"K@#(W<D_,2:^A**;BGHQ)M.Z/C6P_P""$GP%\/ZI:ZAHD/CCP]JM
MC();>_TWQ-<Q7,##NKDG!^E>]>"?V8SX'\+VNE1_$/XG:DEH&"W&HZVMS<R`
ML6PTACRV,X&>P`KU"BDH16R&YR>["BBBJ)"BBB@`HHHH`****`/`_P!K^\U#
MXC^,?"?PYT:*.YGU*<:GJ2NY6-+>(_+YA'.PG)(ZG:H')%6_A?IVO6'[5&L6
M:>)=7US2-,TB,:H+E@+:*\D;<D<,:C;'A!G:.0#@DYKH-;^!VO'XX:EXMT;Q
M#9:<NL6$5A.)K#SY[94QS"2P4$XS\P(SV-=OX$\!:=\.]#^PZ>DI$DK3SSS/
MYD]U,QR\LC'EF)[_`(#``%9<K<KLU<DHV1Y-^U9JOB'6O%/AWPAH&M76G:AX
MAN$,*6+F*2"!,F>>9QSM`P%48SAB<X`';?M!_%67X)?"F;4;:,WVJ2O'8:?'
M(-WG7$GRJ6QU'!)]<8[UF+^SU=7_`,>-8\7W^MR2V=];PVL%G%&4DBB3:QC,
MF<A"ZY(7&[."<9!Z3XP?#%?BAH-C"LT=O>:3J$&IV;R)OC\V)LA77@E2"0<'
M/.>U%I:L+QT1Y?JT^M?"CXA_#.PFUW5-7\2^)KV0:UYMPS6\D/EYD"1?<148
MC:5`.%//)KH_VS/&6I>$?@[-'I5X+:_UJ9=+@C6'?+</+\NU3GY?EW'.">F,
M5N^"_@W)9_$.Y\8^(;Z/5?$<T/V6V\J,QVNFP=XXE))))SER<G)Z"N`^+5KJ
M/QD_:CT/0M)N+>&+P#;KK=PT\3/$]R[+Y<;8(/*@'/49/6DTU%KN--.2\C&T
M_P`*7?[/OQL^%OA?0=5U5XM2M)4UBQ>Z>:U=57+2JC9"?.7/&*ZS]N3Q5<V/
MPGM_#FG++-JOC&]CTR"&(@22(2&<#Z@!?^!UVO@GX4MI?C2]\5:W=QZIXDO8
M1:K)'&8[>PMP<B&%220,Y)8G+'T'%0>+_@[-XK^*^G>*&U01MHFG3VVFVS6P
M=+>YE!!N"2?FP,`+@=.M'*U%I=0YDY)L\F^('A/Q-\-?$WPJL]/\0:M_:E]J
M,=I+IUO/LT^&TB12Z",##;4'+MDMR>.`/:_B9\1AX&M[&UM;?[?KNMS?9=-L
M\X$LF,EW/\,:#YF;L!@<D5G_``\^%NH:9JMOKGBK58?$/B6WM39Q7,5L+>&V
MC)RVQ`3\SG&YN^```!SE_$SX&ZOXU^,>@^*--\2OHJ:39RV<D:VRS2%9#\QC
M+?*K,.,D'&T&FDTM!-INS.*\2IJ7Q!_:&T#PE'XFU6].C#^U_$OV9_(M$VE3
M#;JJ8*Y8\@L20W))''3?MG^,;_P/\&+V\L]4GTPR8MX_LN5N;B=R!&BN/NJ!
MO9L<G:`",FCX+?LOGX5>,]=U2;6)+V'4K\WD,**R/QNV>=(26DV[F..!N.XY
M.,=+\3_@ZGQ2\6^%[R^O`-+\.7;7S6'E9%W,!B,LV>`IYQ@YI*,N5]V/FCS+
MLCE?A1\'_%5]8^$-=\1^+M?M]0TRW03:7%*/L\R;,!)L\O(>K,2>3@8P#6#^
MVCXL\16TNB>'?#VIW=OJWB"ZCCL+73Y#%,X4DRR2OU"#*@`8'WB2<`#WZN$T
MSX,-!\:=7\:WFHB^O;BS6QTR%H<)I<0'S8.[YBS<D\=2.]5*&G*B8SUNSQR\
MU7Q;J?[3=II>E>*]1D?0-/,WB:YDD_XEED63[L</3*K@C=DEN2>#79_L<+J^
MNVGB7Q'<ZQK6H>']8OV718]2N#-*(8RRF;)Z;SV``^6K9_9AN[#X(^(_#MEK
MP&O^*IWN=2UB6WPURSOEEV@Y"[,J.>,GUKO/A?\`#J/X:^&(+!;J2[DCBCB9
MR-D8"*%58X\D(H`Z#DDDDDDFIA%WNRI27+9&%X@^),OB/Q-JNDZ3?1Z9IGAQ
M-VNZPP4_93MW>1%NROF;>68@A`1P2>.4_9(@O_&6H>)/&UUJFL7VF:M<M9Z)
M'>SERMI$Q_>;>F6;OC/RGUK/O/V/M;U#P)XMT&;QBWV+7;^;4+6!+4(D<DD@
M8F9@=\@P,;<@`X/.,5ZE\(?AD/A=X2M=/>]EU"XA@C@:4KY<86-<*L<8.$4<
MGU)))))II2<KL3<5&R.JHHHK4R"BBB@`HHHH`****`"BBB@`HHHH`****`([
MJW%U;21%I$$BE=R-M9<C&0>Q]ZXSP)^S_H/PY\7WNN:9)JZZAJ?_`!^//?R3
MB[/."X<G)&3@]J**32>HTVM#MZ***8@HHHH`****`"BBB@`HHHH`****`"BB
$B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g865285g11s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g865285g11s64.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@%!@<&!0@'!@<)"`@)#!,,#`L+
M#!@1$@X3'!@='1L8&QH?(RPE'R$J(1H;)C0G*BXO,3(Q'B4V.C8P.BPP,3#_
MVP!#`0@)"0P*#!<,#!<P(!L@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P
M,#`P,#`P,#`P,#`P,#`P,#`P,#`P,##_P``1"`!/`+0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BC--9U0
M$LP`%*]@'453;5+%3AKJ('TW4?VK88_X^HO^^JR]M3_F7WE<DNQ<HJF-4L2<
M"ZB)_P!ZK*2(X!5@0>A%5&<9?"[@XM;CZ**0D#J:LD6BDW#U%+F@`HI"1G&:
M3<!QF@!U%)N%&1ZT`+129'K2%@.I%`#J*;N`[BES0`M%&0*3<OJ*`%HHHH`*
M***`$.*XSQ7JLCSFUA)50?FQWKLCUS7G^L(#K4N1D;C7DYI4E"DE%[LZL-%.
M5V5;:R>1QU(/>K_]E2",G;P#CI6A91QP6C3NO`'3UJ]I\IN%+.RJ.NW%>72P
MT'92>K.B55]#E+JS>$\#IWK5\)W\J7@MW8LC#C/8U?U2%&BWC)SV`K*T-<:U
M'@8YHA"5"O'E>XW)5(.YW0.:9*0%SGCO3@>37/\`C;53INB2M$V)Y?W48[EC
MP*^IN><D<O:>-7D^(C6+O_H14P(#T+CG/]*]'!W+Q7C/CS03HFEZ-JEL<3VY
M596!YW9W9_/^=>J>&M3CU71K:ZC;(D0$^Q[BI3*:&>(+/4+F%3IUY]E=,Y)3
M=FO.=#U_Q1JWB:71?[0AB:'=ND$6<X]*]9D;Y6SZ5XWX2NH+/XH:C-=2"*/,
M@W$X&<BFP6QTWB27Q/X9L3?QW\5[#$<NCQ8./7(KH?!OB2+Q)I*W<:[)`=LB
MY^Z:PO'_`(AL[[1I=*TMQ>WET-BQQ?-@>I]*M_#KP]<>'/#[+=_Z^4F1E!Z<
M=*0;ECQIXPMO#J+&B_:+R7B.)>N:HZ;IWB;6X5N=5U$V$<@RL$"X*CW)KCO#
M&?$GQ,FN+L[TA9F53S@*<"O9@N%%&X7L<-K?A_Q#I]J\^CZU+,T8W&*<!MWT
M-;?@74KC5/#EM<WQ_P!).1)QCD$@BM]ER,8S4-K:06B%8(PBDEB!ZGJ::5A7
MN3L1MR:\XN_&KQ_$2.Q63_0<>2WIO]?Z5V'BW54TC0KFZS\^W;&!_$YX`_.O
M,?&7AUM.\+Z=J"-OO8G\V=^Y9CDG\Z38TNI[+$05R.AI]8?@W55UC0+6[#9+
M(`WL1UK<S5(AK4****8A"*\^UE@NMS$GC<:]!-<GXIT9VE-U;KNX^8#K7EYG
M2E4I)QZ'5AI)2U&V<L4ULT+\!AR3_2B*RN(F(65-@X)SS6'#+-"PRC<=L5:%
M_-Y9&&Y(/2O&C632YUJCJ<&GH:MY.L5N$!W`#KWS6?H3[];C.<BJ5U+-,Y(5
MOF]JV/"VES+<?:IU*`#Y0:NFYUZ\;+832A!W.M8XK@M:C'BGQE'IR.PM=.7?
M,5./G/05U6OC4GMQ'I0B$C<%I"<#WKF/"?AW7]!OKB::6VN1>2;YFY#`U]0S
MST6-?\$VUSI%S&+BYE;82JO(2`PZ5B_!C5F\BZTB<XDMV+*#]>1^=>@:I]L^
MQM]@6-ICV<X%>=6G@3Q'9ZU)J]K>6L4TCEV0`X(/44,:/3I&_=MG).*\<\)6
MT-W\3]1BN$61#YGRL,]Q7I$S>(#IJ+'';"[)(;+':!V-<=I7@CQ'I6N/K$=U
M:27$A.]2"`<]:3!:&5XRTB?P5XDAUK24Q:R/\R`<`]Q]#7J&AZK;ZYH\=W;-
ME9%P0.Q[BHKW2GUS0Y+35TCWRK@[>0I]17)>%O"?B;PS))]CO+:6W9B?*?//
MO]:`N<YH3?\`"+?$N2*\^2*=V56/0ACD'\Z]I1PX!!R#T-<QXC\)0>);",WR
MB*]1?EECZJ?K5'2K?Q5H40MIA#J<"<(P.UP/?-&P;G:LP!JC8ZQ:WU[=VMN2
M[6C!9"!P"1G%<_J3^*]3@:"SAAL`XVF1VW,/IBH]!\/:MX>T1[>UEAGO9I&>
M25\@$FG<+=RIXG(\2>*[30XF;[-;#[1.5[$?=']:OZGX)MKC39XOM%RY9#M#
M2$C/TJAX=\.^(=&U>>]GEM;HW;`R'D%?I79Z@;I;1S:*C38P`YP*5@;/-O@Y
MJ;6=W?:%=-M>-BZ*?KAJ]4W5Y;_P@GB-?$#:U;75K!<%]^T`X^E=[HS:N6(U
M-(``.#&3R::$S7!HH`XHJB`(YIK(&Z\TX#%+2L,A^S0D_P"K7\J/LT'_`#R3
M\JFI,5/)'L%V0_9H<_ZM1^%2;%`P.*=B@]*:BEL%V12G:C'T&:IZ->27D#32
M*%!8[1GM47B&Y>.S$,7^LG.Q:JZ1`Z7H$<C-#$FUO0GVHZE6T-:[GEA,7EPF
M3>^&P?NCUJ?<,#)K%MI7N-<D*R,8H@5QV+57OKV222Z?>4C@^5%!ZM3N%CH7
M;"DYZ=Z;#*DR;XW#CU%9.I7$T.A(7;$\@"_B:@TB)[?55@A=C"D7[STW47%8
MT-0OI+>[MK>-0?.;!.>@K17IZUSDQ^UZK<3ERD%NNS/^UWQ5JSN9+#21-<L6
M9C\N3R<GBBX[&R2!U(I"1ZXYK`CF>[U2.(3L1'\TF#QGL*DU)KB75H+:WF91
M]]\=A1<5C;'L:,@?Q5G72_V=ITA,[LW8GDY/:L-&NU^SQO<,'CS++S]P=A2;
M!*YUN<].:4\#DBL;19GCLI[N>4E"2X!.<"J=W>RW;PQK(4:8@X!^ZE.X6.ES
M2A<=Z;"FV-1G.!UIY%,0`'UHI:*!!1110`4444`%(W2EHH`JW=G!=A1.F0AR
M#Z&I(H4C3;&NU?:I0!BEQ0.Y6M[2&W=FB0*7.6/J:8VG6QG,IC!8\GTS5O`I
M<4K!<Q[^QDO=0MA(G^C199N>I[5?@M8H!B-<=S[U8P,YHVC-`7*9TVVR/W0Q
MN+8]S4EU:0W4/E3(&0=JL8XQ0!0!4@L+>"5I(H@KOU-3);1K*TH4;VX)J7%&
M*87(;BVCN`HE4,%.0#ZU&UA;N9<Q*?-&']ZMXHI!<K)9PI;?9Q&/+QC;[5$F
>EVL;(R0J"@POL*O8I,46"XB\<8IU%%,04444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
